newsfilter
← Latest News
Business Wire·

Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI® Tablet Formulation for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome

- Tablet authorization builds upon established use of LIVMARLI oral solution in Canada Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a leading rare disease company, today announced that Health Canada has authorized the